{"id":"varivax-vaccine","safety":{"commonSideEffects":[{"rate":"19-35%","effect":"Injection site reactions (erythema, swelling, tenderness)"},{"rate":"10-15%","effect":"Fever"},{"rate":"3-5%","effect":"Varicella-like rash (vaccine strain)"},{"rate":"1-2%","effect":"Myalgia"},{"rate":"1-2%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The vaccine contains a weakened form of the varicella-zoster virus (Oka strain) that replicates in the body at low levels, triggering both humoral (antibody) and cell-mediated immune responses. This primes the immune system to recognize and rapidly respond to natural varicella-zoster virus infection, preventing or significantly reducing the severity of chickenpox and reducing the risk of herpes zoster (shingles) later in life.","oneSentence":"Varivax is a live attenuated varicella-zoster virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus that causes chickenpox.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:19.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of varicella (chickenpox) in children and adults"},{"name":"Prevention of herpes zoster (shingles) in adults ≥50 years of age"}]},"trialDetails":[{"nctId":"NCT05923970","phase":"","title":"Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2024-11-09","conditions":"Vaccination Failure, Vaccine Response Impaired","enrollment":200},{"nctId":"NCT07473427","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children Aged 1~12 Years: A Single-armed Bridging Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-05-01","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT07475000","phase":"PHASE3","title":"Second Dose of Varicella Vaccine in Healthy Children","status":"RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2026-01-28","conditions":"Varicella (Chickenpox), Varicella Immunisation","enrollment":300},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT06975878","phase":"PHASE3","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":1092},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT07415252","phase":"PHASE3","title":"SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-06-05","conditions":"Varicella (Chickenpox)","enrollment":780},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07406360","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-04-13","conditions":"Measles","enrollment":1209},{"nctId":"NCT03621670","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-07-27","conditions":"Infections, Meningococcal","enrollment":1196},{"nctId":"NCT07400003","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2026-01-06","conditions":"Herpes Zoster, mRNA Vaccine","enrollment":519},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05622682","phase":"","title":"Vaccine Immune Recovery After Leukemia","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2022-09-28","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":89},{"nctId":"NCT01953900","phase":"PHASE1","title":"iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2014-04","conditions":"Osteosarcoma, Neuroblastoma","enrollment":26},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT07170059","phase":"","title":"Observational Study on the Impact of Herpes Zoster Vaccine on the Incidence of Herpes Zoster and Survival in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-10-01","conditions":"Lung Cancer","enrollment":500},{"nctId":"NCT03604406","phase":"PHASE2","title":"The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kevin Winthrop","startDate":"2014-05-08","conditions":"Herpes Zoster, Inflammatory Disease, Rheumatoid Arthritis","enrollment":154},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT07054099","phase":"PHASE3","title":"A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years","status":"NOT_YET_RECRUITING","sponsor":"GC Biopharma Corp","startDate":"2026-03","conditions":"Varicella (Chickenpox), Chickenpox Vaccine","enrollment":474},{"nctId":"NCT05630846","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-12-14","conditions":"Measles; Mumps; Rubella; Chickenpox, Measles","enrollment":801},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT06994052","phase":"PHASE4","title":"Study on Booster Immunization With Varicella Vaccine at Different Intervals","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"VZV, Varicella Immunisation","enrollment":412},{"nctId":"NCT06987942","phase":"PHASE4","title":"Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-21","conditions":"Varicella, Influenza Vaccine","enrollment":899},{"nctId":"NCT06961721","phase":"PHASE4","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older","status":"NOT_YET_RECRUITING","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2025-05","conditions":"Prevention of Herpes Zoster","enrollment":600},{"nctId":"NCT06891872","phase":"PHASE4","title":"Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2025-05","conditions":"Varicella (chickenpox), MMR Vaccine, DTaP Vaccine","enrollment":720},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT06851832","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Chinese Population Aged 40 Years and Older","status":"RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-02-16","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":960},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06801509","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-02-15","conditions":"Herpes Zoster","enrollment":540},{"nctId":"NCT05095701","phase":"PHASE4","title":"An Immunity Persistence Study of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-12-18","conditions":"Varicella","enrollment":703},{"nctId":"NCT06314724","phase":"PHASE3","title":"Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-02-29","conditions":"Varicella","enrollment":642},{"nctId":"NCT06482216","phase":"","title":"Correlation of Protection Against Varicella in an Exploratory Study","status":"NOT_YET_RECRUITING","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2025-10-10","conditions":"Varicella","enrollment":400},{"nctId":"NCT06484686","phase":"PHASE4","title":"An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2024-09-16","conditions":"Varicella","enrollment":414},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT04169009","phase":"PHASE4","title":"Persistence of Protection by Shingrix","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-07-28","conditions":"Herpes Zoster","enrollment":105},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT06614816","phase":"PHASE3","title":"Immunogenicity and Safety of a Live Attenuated Varicella Vaccine in Children Aged 1-12 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-02-10","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT05871541","phase":"PHASE1","title":"A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine","status":"COMPLETED","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2023-05-26","conditions":"Herpes Zoster (HZ), Shingles, Infectious Disease","enrollment":75},{"nctId":"NCT06592456","phase":"PHASE3","title":"A Phase III Clinical Trial Assessing the Immunogenicity and Safety of Lyophilized Live-Attenuated Varicella Vaccine in Healthy Subjects Aged 13 to 55 Years","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-07-21","conditions":"Chickenpox Vaccines","enrollment":1200},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT03771157","phase":"EARLY_PHASE1","title":"Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2019-02-01","conditions":"Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)","enrollment":33},{"nctId":"NCT06313762","phase":"NA","title":"Use of Virtual Reality in the Reduction of Pain After the Administration of Vaccines Among Children in Primary Care Centers.","status":"COMPLETED","sponsor":"Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina","startDate":"2022-01-18","conditions":"Pain, Pediatrics, Vaccination","enrollment":300},{"nctId":"NCT05015686","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"ENROLLING_BY_INVITATION","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-09-30","conditions":"Varicella","enrollment":2400},{"nctId":"NCT03993717","phase":"","title":"Solid Organ Transplant SHINGRIX","status":"TERMINATED","sponsor":"Emory University","startDate":"2020-01-30","conditions":"Kidney Transplant; Complications","enrollment":2},{"nctId":"NCT05422508","phase":"PHASE2","title":"Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination","status":"RECRUITING","sponsor":"Green Cross Corporation","startDate":"2022-07-05","conditions":"Varicella","enrollment":230},{"nctId":"NCT05158777","phase":"PHASE3","title":"Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-02-13","conditions":"Varicella","enrollment":2480},{"nctId":"NCT04072497","phase":"PHASE1, PHASE2","title":"A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-20","conditions":"Herpes Zoster","enrollment":522},{"nctId":"NCT01911065","phase":"PHASE4","title":"T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Herpes Zoster","enrollment":54},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT05047770","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-07","conditions":"Herpes Zoster","enrollment":2013},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT05952505","phase":"PHASE4","title":"Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines","status":"UNKNOWN","sponsor":"Shanghai Municipal Center for Disease Control and Prevention","startDate":"2023-08","conditions":"SARS-CoV-2 Infection, Varicella, Measles","enrollment":540},{"nctId":"NCT04384016","phase":"PHASE4","title":"Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old","status":"COMPLETED","sponsor":"Vietnam Military Medical University","startDate":"2021-04-17","conditions":"Chickenpox","enrollment":201},{"nctId":"NCT05839301","phase":"PHASE3","title":"A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Years of Age","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2023-04-27","conditions":"Varicella","enrollment":1200},{"nctId":"NCT05669625","phase":"PHASE3","title":"A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2022-12-26","conditions":"Varicella","enrollment":12440},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT05130398","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2021-04-09","conditions":"Ebola Virus Disease","enrollment":120},{"nctId":"NCT01693380","phase":"PHASE4","title":"Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2009-05","conditions":"Influenza, Acute Respiratory Infection","enrollment":1742},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT05460429","phase":"PHASE4","title":"Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level and Etiology of Varicella Zoster Virus","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-30","conditions":"Varicella","enrollment":37920},{"nctId":"NCT05470855","phase":"PHASE4","title":"Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province","status":"UNKNOWN","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2022-07-06","conditions":"Varicella","enrollment":45400},{"nctId":"NCT05664152","phase":"NA","title":"An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years","status":"UNKNOWN","sponsor":"GC Biopharma Corp","startDate":"2023-02","conditions":"Varicella Zoster Virus Infection","enrollment":250},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":"Varicella","enrollment":450},{"nctId":"NCT01600079","phase":"","title":"ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-15","conditions":"Herpes Zoster, Shingles","enrollment":1505647},{"nctId":"NCT00940940","phase":"PHASE4","title":"Safety and Immunogenicity of Zostavax Vaccine in Patients Undergoing Living Donor Kidney Transplantation","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2009-10","conditions":"Kidney Transplant","enrollment":4},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01190228","phase":"PHASE3","title":"Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08-25","conditions":"Japanese Encephalitis, Varicella","enrollment":454},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT05150392","phase":"PHASE3","title":"An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence After Primary Immunization and Safety and Immunogenicity After the Booster Immunization","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2018-07-11","conditions":"Varicella","enrollment":1193},{"nctId":"NCT04334577","phase":"PHASE3","title":"Study on Efficacy of Attenuated Zoster Vaccine, Live","status":"COMPLETED","sponsor":"Changchun BCHT Biotechnology Co.","startDate":"2020-04-20","conditions":"Herpes Zoster","enrollment":25000},{"nctId":"NCT02538341","phase":"PHASE2","title":"Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2016-05","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Arthritis","enrollment":617},{"nctId":"NCT00851786","phase":"PHASE2","title":"Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-04-29","conditions":"Herpes Zoster, HIV Infections","enrollment":395},{"nctId":"NCT00001125","phase":"PHASE1","title":"Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Chickenpox","enrollment":60},{"nctId":"NCT00000837","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":127},{"nctId":"NCT00432523","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-01-20","conditions":"Measles, Mumps, Varicella","enrollment":752},{"nctId":"NCT00213304","phase":"PHASE3","title":"The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"1999-06","conditions":"Organ Transplantation, Immunosuppression","enrollment":21},{"nctId":"NCT00681031","phase":"PHASE4","title":"Zostavax® at Minimum Release Specification Approaching Expiry (V211-044)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05-14","conditions":"Herpes Zoster","enrollment":96},{"nctId":"NCT01262300","phase":"PHASE1","title":"Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2010-11","conditions":"Immunosenescence, Shingles","enrollment":33},{"nctId":"NCT02075515","phase":"PHASE3","title":"Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-13","conditions":"Herpes Zoster, Herpes Zoster Vaccine","enrollment":651},{"nctId":"NCT03375502","phase":"PHASE2, PHASE3","title":"A Study of MG1111 in Healthy Children","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2016-11-26","conditions":"Healthy Children","enrollment":814},{"nctId":"NCT03843632","phase":"PHASE3","title":"Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-01","conditions":"Varicella","enrollment":150},{"nctId":"NCT02026089","phase":"PHASE4","title":"Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2021-12","conditions":"Persistence of Varicella Immunity","enrollment":""},{"nctId":"NCT03239873","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-17","conditions":"Varicella","enrollment":600},{"nctId":"NCT01681992","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-10","conditions":"Measles, Mumps, Rubella","enrollment":4538},{"nctId":"NCT02184572","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-08-25","conditions":"Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine","enrollment":1742},{"nctId":"NCT00492739","phase":"PHASE2, PHASE3","title":"Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2007-06","conditions":"Liver Disease, Immunosuppression, Varicella","enrollment":80},{"nctId":"NCT02114333","phase":"PHASE1","title":"Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-05","conditions":"Shingles, Herpes Zoster","enrollment":160},{"nctId":"NCT03563183","phase":"","title":"A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-05","conditions":"Herpes Zoster","enrollment":26976},{"nctId":"NCT03330171","phase":"PHASE4","title":"Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine","status":"UNKNOWN","sponsor":"University of Witwatersrand, South Africa","startDate":"2017-04-10","conditions":"Measles, Varicella, Hepatitis A","enrollment":278},{"nctId":"NCT01506661","phase":"PHASE1","title":"Safety of Zostavax Vaccination in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Oklahoma Medical Research Foundation","startDate":"2012-01","conditions":"Rheumatoid Arthritis, Varicella Zoster","enrollment":20},{"nctId":"NCT03016884","phase":"PHASE4","title":"Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-01","conditions":"Herpes Zoster","enrollment":87},{"nctId":"NCT00861744","phase":"PHASE2","title":"Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-03","conditions":"Rubella, Mumps, Measles","enrollment":1259},{"nctId":"NCT02590068","phase":"NA","title":"Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination","status":"TERMINATED","sponsor":"Rockefeller University","startDate":"2015-12","conditions":"Hepatitis C","enrollment":14},{"nctId":"NCT02624375","phase":"PHASE4","title":"Immune Response to Shingles Vaccination","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-02","conditions":"Shingles","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VARIVAX™","Varivax®"],"phase":"phase_3","status":"active","brandName":"Varivax vaccine","genericName":"Varivax vaccine","companyName":"Sanofi","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"Varivax is a live attenuated varicella-zoster virus vaccine that stimulates the immune system to produce antibodies and cellular immunity against the virus that causes chickenpox. Used for Prevention of varicella (chickenpox) in children and adults, Prevention of herpes zoster (shingles) in adults ≥50 years of age.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}